RadioMedix, Inc.

In late October 2024, the first patient in a trial of Ariceum’s radioligand therapy (RLT) for glioblastoma, an aggressive brain cancer, showed 50% tumor shrinkage after just four to six weeks of tre

The radiopharmaceutical space saw a couple of huge deals at the end of last year, and another flurry, albeit on a rather smaller scale, happened this week. On September 12, both Sanofi and ITM Isot

Amidst a continued chilly environment for novel approvals, the US FDA’s breakthrough therapy designation (BTD) program has been generating heat this month, with seven new awards announced in February,

A US Food and Drug Administration advisory committee generally supported a proposal that would eliminate the need for animal dosimetry data for some new positron emission tomography (PET) drugs, altho